Getting Personal: The Future of Medicine and Clinical Trials
Horgan D. (Brussels)
Lawler M. (Belfast)
Satyamoorthy K. (Manipal)
Brand A. (Maastricht)
Publication year: 2015
|Buy this book|
|Digital Version:||CHF 29.00, EUR 27.00, USD 34.00|
|Print Version:||CHF 29.00, EUR 27.00, USD 34.00|
|The final prices may differ from the prices shown due to specifics of VAT rules, postage and handling.|
|Order this title|
You already have online access to this title. If you would like to buy a personal digital or print copy, please click here.
There are various challenges now to facilitate an accelerated ‘concept-to-clinic’ culture, but in a way that translates preliminary discovery ‘hits’ into robust but affordable clinical ‘wins’ for patients. In this special issue of Public Health Genomics, several stakeholders outline the key challenges and the potential solutions that will help embed PPM in evolving innovative clinical trial frameworks. These have been brought together by the Brussels-based European Alliance for Personalised Medicine, a multi-stakeholder organisation that includes patient groups, researchers, front-line healthcare professionals, industry representatives and more, and is in regular discussions with the European Council, Commission, Parliament and Member State governments as it aims to see PPM integrated into healthcare systems across the EU.